Randomized Crossover Trial to Compare Abuse Liability of Intravenous Remimazolam Versus Intravenous Midazolam and Placebo in Recreational Central Nervous System Depressant Users

Remimazolam (RMZ) is a new and ultra‐fast‐acting, short‐duration intravenous benzodiazepine, a drug class associated with abuse potential. This trial was designed to compare the abuse potential of remimazolam with placebo and midazolam (MDZ), a well‐characterized member of the same pharmacological c...

Descripción completa

Detalles Bibliográficos
Autores principales: Schippers, Frank, Pesic, Marija, Saunders, Robert, Borkett, Keith, Searle, Shawn, Webster, Lynn, Stoehr, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
NON COVID ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496124/
https://www.ncbi.nlm.nih.gov/pubmed/32495449
http://dx.doi.org/10.1002/jcph.1614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496124/
https://www.ncbi.nlm.nih.gov/pubmed/32495449
http://dx.doi.org/10.1002/jcph.1614

Ejemplares similares